Home Multimedia Podcasts Drug Repositioning as a Viable Business Model Drug Repositioning as a Viable Business Model March 10, 2011 Aris Persidis, Ph.D., President, Biovista /wp-content/uploads/2018/09/gencast_030911.mp3 PodcastsResourcesBusiness ethicDrugsEthicsEthics, law and policyPharmacology Also of Interest Gene Network Interactions Shed Insight into Breast Cancer Onset and Development StockWatch: Regeneron Shares Dip as DOJ Alleges Fraudulent Price Reporting China Upholds Key CVC CRISPR Patent Licensed through ERS Genomics Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline CRISPR Concerns Won’t Spoil Its Promise—If We Use the Right Tools Seaport Therapeutics Launches with $100M Series A Related Media BIO CEO Rachel King Outlines Industry's Challenges on "Close to the Edge" Emerging Markets Collaborate to Succeed in Post-Pandemic World Book Review: The Exceptions Global Single-Use Network Support Assurance of Supply Resins Address Downstream Purification Concerns Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies Related Content Gene Network Interactions Shed Insight into Breast Cancer Onset and Development StockWatch: Regeneron Shares Dip as DOJ Alleges Fraudulent Price Reporting China Upholds Key CVC CRISPR Patent Licensed through ERS Genomics Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline